Migalastat

(Galafold)

Migalastat

Drug updated on 11/16/2023

Dosage FormCapsule (oral; 123 mg)
Drug ClassAlpha-galactosidase A pharmacological chaperones
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

Product Monograph / Prescribing Information

Document TitleYearSource
Galafold (migalastat) Prescribing Information.2021Amicus Therapeutics, Cranbury, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinical review report: migalastat (Galafold). 2018CADTH

Clinical Practice Guidelines